Endo spikes on pain drug approval; Groove gathers $6M in venture cash; Regulus launches microRNA program for brain cancer;

@FierceBiotech: Interesting piece from @eyeonfda on social media guidelines and clinical trials. Article | Follow @FierceBiotech

 @JohnCFierce: Abbott bets $400M on Reata preclinical-in which CEO Huff laughs, tells me "no comment" on Abbott buyout bid. | Follow @JohnCFierce

@RyanMFierce: Say lots about FDA, but France's drug regulatory system looks like a mess in comparison. Article on Mediator scandal. | Follow @RyanMFierce

 @MaureenFierce: Writing for New Scientist, the CEO of the UK's Science Media Center proposes 5 way to fix science journalism. Article | Follow @MaureenFierce

> Shares of Endo Pharmaceuticals jumped today on the news that the FDA has approved its crush-resistant formulation of the pain drug Opana. Report

> Seattle-based Groove Biopharma, formerly Mirina, has reportedly gathered $6 million in venture cash to back its work on microRNA therapies. Story

> La Jolla, CA-based Regulus Therapeutics has launched a discovery program for a new microRNA treatment for glioblastoma, the most common form of brain cancer, with financial help from the nonprofit Accelerate Brain Cancer Cure (ABC2). Release

> Ireland's Elan is contributing more than three million euros to UCD to establish a new chair for the "Business of Biotechnology." Story

> Canada's Aeterna Zentaris says it has gathered promising preclinical data for its oral anticancer Akt inhibitor, perifosine, in Hodgkin lymphoma. Release

> Canadian officials have approved AMAG's anemia drug Feraheme. Story

Pharma News

 @FiercePharma: NHS data on prescriptions to be opened up to public under open data initiative. Story | Follow@FiercePharma

> Ex-Shionogi employee sentenced for hacking. Report

> Study: Eli Lilly's Cymbalta sputters out for nearly 16% of depression patients. News

> Mediator probe enlightens French public on drug risks. Item

> Pfizer seeks 2nd chance for cancer drug Mylotarg. Story

> Bayer bracing for profit-margin drop. Article

Biotech IT News

> Pharma hacker gets jail sentence in NJ. Story

> Supercomputer software aids UK cancer researchers. Report

> IBM taps 'Watson-type' tech for drug research tool. Item

> Uncle Sam to award $20M for work on genomic data informatics. Report

> U. Cal professor recruits computer whizzes for war on cancer. Article

> U.K. injecting £75M into bioinformatics 'nerve center' for Europe. News

Medical Device News

> Bluegrass announces patient enrollment in catheter trial. News

> Boston Sci introduces Charger catheter. Report

> Tissue Regenix to raise $39M, eyes job creation. Article

> Symmetry to buy instruments biz of J&J unit for $165M. Story

And Finally... Professor Victor Zammit at the Warwick Medical School says he found that an enzyme known as 'Carnitine palmitoyltransferase 1A' (CPT1) has a switch which is thrown depending on the composition and curvature of its cellular membrane, shedding light on a possible new mechanism to controlling appetite. Report

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.